unfortunately one research outcome is usually contradicted by another and in the case of longini , the research abstract i read several weeks ago supported the view that zanamivir showed greater efficacy against mutating strains than oseltamivir(tamiflu)
and whilst gsk are planning to spend wads to build a vaccine fluarix, it seems rather imperious to state that it will be ready by 2008.
they are not the only ones in the race to build a vaccine.
and what about the newer neuraminidase inhibitors and ongoing other strains of flu that biota are targetting.
- Forums
- ASX - By Stock
- BTA
- dead as
dead as, page-18
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online